Helene Shea

Helene Shea has a diverse work experience in the pharmaceutical industry, spanning over two decades. Helene is currently working as the Vice President CMC at Promontory Therapeutics since July 2022. Prior to this, they held the position of Vice President, Head of CMC at Saniona from March 2022 to June 2022, and Sr. Director, Head of CMC from January 2021 to March 2022. Before joining Saniona, they worked at AMAG Pharmaceuticals from 2014 to 2021, where they held various roles including Sr. Director, CMC from August 2018 to January 2021, Director Drug Substance Manufacturing from March 2016 to August 2018, and Associate Director, Drug Substance Manufacturing from January 2014 to March 2016.

Before their tenure at AMAG Pharmaceuticals, Helene worked at ARIAD Pharmaceuticals, Inc. as a Sr. Manager, Drug Substance Operations. In this role, they were responsible for the manufacture of drug substance and CMC project management for the AP26113 program. Helene was also involved in tech transfer of processes, managing timelines, and coordinating cross-functional team activities.

Prior to ARIAD Pharmaceuticals, Helene worked at Johnson Matthey Pharma Services as a Principal Scientist/Coordinator from 2002 to 2012, and at Albemarle Corporation as a Sr. R&D Specialist from 1997 to 2002.

Helene's career in the pharmaceutical industry began with their role as a Post Doctoral Research Associate at Texas A&M University from 1996 to 1997.

Helene Shea earned a Bachelor's degree in Chemistry from the College of the Holy Cross between 1986 and 1990. Subsequently, they pursued their academic aspirations and obtained a PhD in Organic Chemistry from Dartmouth College from 1990 to 1995.